Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Stragand

Nurse Practitioner Beaver, PA Nurse Practitioner

NPI 1558768549 CMS profile 11037614

628 River Rd, Beaver, PA 15009

Open in the dashboard

General payments

$2,073

74 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Stragand of Beaver, PA is reported in the CMS Open Payments database as having received $2,073 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $67 1
2024 General $831 29
2023 General $851 36
2022 General $40 2
2021 General $284 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Stragand
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Stephanie Stragand were reported at $67. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Stephanie Stragand Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $284 $135 $40–$426 $132
2022 $40 $152 $48–$470 $149
2023 $851 $166 $54–$529 $160
2024 $831 $173 $55–$556 $164
2025 $67 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $564 21 payments
  2. AstraZeneca Pharmaceuticals LP $523 15 payments
  3. Regeneron Healthcare Solutions, Inc. $247 7 payments
  4. Jazz Pharmaceuticals Inc. $83 3 payments
  5. Genzyme Corporation $83 3 payments
  6. Caris MPI, Inc. $67 1 payment
  7. Takeda Pharmaceuticals U.S.A., Inc. $57 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $50 3 payments
  9. Amgen Inc. $45 2 payments
  10. Genentech USA, Inc. $41 2 payments
  11. Other $314 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,050 73 payments
  2. Education $23 1 payment
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $366 16 payments
  2. DUPIXENT Inflammation And Immunology $247 7 payments
  3. AREXVY $125 1 payment
  4. BREZTRI $122 2 payments
  5. AIRSUPRA $113 6 payments
  6. FASENRA $112 4 payments
  7. XYWAV $83 3 payments
  8. DUPIXENT Immunology $83 3 payments
  9. TEZSPIRE $77 3 payments
  10. NUCALA $73 4 payments
  11. Other $573 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,227

Median for Nurse Practitioner: 389

Drug cost

$468,900

Median for Nurse Practitioner: $21,885

Branded share of claims

73.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 345 $297,115
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 72 $36,007
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 66 $34,026
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 37 $28,611
Breo Ellipta Fluticasone/Vilanterol Brand 37 $23,944
Spiriva Respimat Tiotropium Bromide Brand 20 $12,527
Advair Hfa Fluticasone Propion/Salmeterol Brand 16 $7,734
Albuterol Sulfate Hfa Albuterol Sulfate Brand 168 $6,326
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 22 $6,033
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 28 $5,001

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$17,870

Medicare's payments for the services billed

Medicare patients

157

Average age 72

Services billed

229

89 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 52%
Arthritis 50%
Depression 34%
Ischemic heart disease 33%
Diabetes 31%
Chronic kidney disease 29%
Heart failure 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $163
  • GENZYME CORPORATION $39
$202 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $102
$102 345 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $63
$63 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $62
$62 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record